Journal article

Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study

Natalie Hyde, Seetal Dodd, Kamalesh Venugopal, Christa Purdie, Michael Berk, Adrienne O'Neil

CURRENT DRUG SAFETY | BENTHAM SCIENCE PUBL | Published : 2015

Abstract

BACKGROUND: The efficacy of clozapine for the treatment of schizophrenia has been demonstrated. However, a range of adverse events have been associated with its use. To date, there remains a paucity of data regarding the prevalence of clozapine-induced cardiovascular (CV) and parameters associated with the development of metabolic syndrome, alongside associated risk factors for their development. METHODS: An observational, clinical cohort study design of 355 clozapine patients who were enrolled in the Barwon Health Clozapine Program at Geelong Hospital, Victoria, Australia, between 2008-12. Medical records were accessed retrospectively. Multivariate logistic regression was used to determine ..

View full abstract

Grants

Awarded by NHMRC Senior Principal Research Fellowship


Awarded by National Health and Medical Research Council (NHMRC)


Funding Acknowledgements

MB has received Grant/Research Support from the NIH, and is supported by a NHMRC Senior Principal Research Fellowship 1059660, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, MaynePharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, SanofiSynthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier.SD has received Grant/Research Support from the Simons Autism Foundation, NHMRC, Beyond Blue, Bristol Myers Squibb, Eli Lilly, Novartis, MaynePharma and Servier, has been a speaker and served as a consultant for Eli Lilly. AO is supported by Early Career Fellowships (ECF) from the National Health and Medical Research Council (NHMRC, #1052865). NH is supported by an Australian Postgraduate Award (APA).